Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration, the Biden campaign and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
Featured Prescription Drugs Resources
KFF Health Tracking Poll – October 2019: Health Care In The Democratic Debates, Congress, And The Courts
This poll examines health care issues in the Democratic presidential primary , government negotiation of prescription drug prices, party trust on health care, Medicare-for-all, and the pending Texas v. US lawsuit affecting the Affordable Care Act and pre-existing condition protections.
Poll Finding See More
Related Prescription Drugs Resources
- Assessing Drug Price Increases in Medicare Part D and the Implications of Inflation Limits
- 10 FAQs on Prescription Drug Importation
- Pricing and Payment for Medicaid Prescription Drugs
- Management and Delivery of the Medicaid Pharmacy Benefit
- Understanding the Medicaid Prescription Drug Rebate Program
- A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries
- Kaiser Health News Coverage of Prescription Drug Issues
- What are the recent and forecasted trends in prescription drug spending?
- What’s the Latest on Medicare Drug Price Negotiations?
- How Will The Medicare Part D Benefit Change Under Current Law and Leading Proposals?
- Medicaid’s Prescription Drug Benefit: Key Facts
- Public Opinion on Prescription Drugs and Their Prices
- Prescription Drug Rebates, Explained
- Who is Most Likely to Have High Prescription Drug Costs?
- Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
- 10 Essential Facts About Medicare and Prescription Drug Spending
- Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs
- How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?
What’s the Latest on Prescription Drug Proposals from the Trump Administration, Congress, and the Biden Campaign?
This slideshow explains the similarities and differences among major proposals to lower prescription drug costs introduced by the Trump Administration, members of Congress, and the Biden campaign.
Slideshow See More
- view as grid
- view as list
This Medicare Part D data spotlight focuses on the use of specialty tiers for high-cost and injectible drugs in Medicare Prescription Drug Plans in 2008. It finds that the number of plans with specialty tiers has nearly doubled since 2006. It also looks at the drugs assigned to specialty tiers,…Issue Brief Read More
This document contains the detailed toplines from the Kaiser Health Tracking Poll: Election 2008 – April 2008. Toplines (.pdf)Poll Finding Read More
Examining Sources of Supplemental Insurance and Prescription Drug Coverage Among Medicare Beneficiaries: Findings from the Medicare Current Beneficiary Survey, 2007
This updated chartpack presents sources of supplemental and prescription drug coverage among Medicare beneficiaries in 2007, the most recent year for which national data are available. The chartpack looks at variations in supplemental and prescription drug coverage by income, race/ethnicity, age, urban/rural location, and health status. It also examines characteristics…Report Read More
The Public’s Health Care Agenda for the New President and Congress This survey captures the public’s attitudes regarding the health care agenda for President Obama and the new Congress in 2009. It assesses the relative priority placed on health care by the American public as part of addressing the…Poll Finding Read More
Prescription Drug Coverage for Medicare Beneficiaries: A Side-by-Side Comparison of S. 1 and H.R. 1 and the Conference Agreement H.R. 1
This document, prepared by Health Policy Alternatives, Inc., provides a detailed side-by-side comparison of the prescription drug provisions of the Conference Agreement (H.R. 1) passed by the House and Senate in November 2003 and the House (H.R. 1) and Senate (S. 1) Medicare proposals passed in June 2003.Report (.pdf)Report Read More
The New Medicare Prescription Drug Law: Issues for Dual Eligibles with Disabilities and Serious Conditions
The New Medicare Prescription Drug Law: Issues for Dual Eligibles with Disabilities and Serious ConditionsThe new issue paper discusses the challenges the new Medicare drug program faces in meeting the needs of dual eligible individuals with disabilities, who tend to have extensive, complex and varying needs. The brief examines four…Issue Brief Read More
This comprehensive survey of people on Medicare, conducted in June and July 2004, assesses their attitudes toward the new Medicare drug law. This chartpack, issued in September 2004, presents additional analysis on the survey data, focusing on the views of people under age 65 with physical and/or mental disabilities.Supplemental Chartpack…Report Read More
State Medicaid Outpatient Prescription Drug Policies: Findings from a National Survey, 2005 UpdateThis survey of state Medicaid pharmacy programs supplements surveys conducted in 2003 and 2000 and reports Medicaid prescription drug policies in effect in early 2005. It covers key elements of utilization management, drug purchasing and potential impacts of…Poll Finding Read More
For a number of years, Governors and other state policymakers have maintained that Medicare – rather than state Medicaid programs – should play the key role in providing prescription drug coverage to Medicare beneficiaries, including those who also qualify for Medicaid because they are impoverished and/or have extensive health care…Issue Brief Read More
This Medicare Part D data spotlight examines the benefit design of Medicare Part D Prescription Drug Plans (PDP) in 2008, focusing on national plans. It shows that in 2008, as in previous years, only about 10 percent of national prescription drug plans offered the defined standard benefit. The spotlight also…Issue Brief Read More